Replimune Group, Inc.
General ticker "REPL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $688.8M (TTM average)
Replimune Group, Inc. follows the US Stock Market performance with the rate: 30.3%.
Estimated limits based on current volatility of 3.8%: low 11.15$, high 12.03$
Factors to consider:
- Total employees count: 465 (-2.9%) as of 2026
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Platform development, Commercialization challenges, Market competition
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-03-31 to 2028-03-30
- 2026-03-31 to 2027-03-31 estimated range: [4.61$, 12.03$]
- 2027-03-31 to 2028-03-30 estimated range: [4.10$, 10.84$]
Financial Metrics affecting the REPL estimates:
- Negative: with PPE of -2.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 46.12 > 2.08
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 1.31 <= 1.42
Short-term REPL quotes
Long-term REPL plot with estimates
Financial data
| YTD | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $234.77MM | $261.63MM | $319.92MM |
| Operating Income | $-234.77MM | $-261.63MM | $-319.92MM |
| Non-Operating Income | $19.39MM | $14.80MM | $5.43MM |
| Interest Expense | $6.66MM | $7.89MM | $8.86MM |
| R&D Expense | $174.96MM | $189.45MM | $221.18MM |
| Income(Loss) | $-215.39MM | $-246.83MM | $-314.49MM |
| Taxes | $0.41MM | $0.47MM | $-0.55MM |
| Net Income(Loss)* | $-215.79MM | $-247.30MM | $-313.94MM |
| Stockholders Equity | $374.51MM | $415.84MM | $166.16MM |
| Assets | $487.72MM | $551.33MM | $332.39MM |
| Operating Cash Flow | $-185.47MM | $-192.25MM | $-280.34MM |
| Capital expenditure | $5.66MM | $6.69MM | $4.22MM |
| Investing Cash Flow | $97.20MM | $-23.80MM | $310.84MM |
| Financing Cash Flow | $16.28MM | $252.40MM | $66.29MM |
| Earnings Per Share** | $-3.24 | $-3.07 | $-3.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.